KW-3357

DRUG4 trials

Sponsors

Kyowa Kirin Co., Ltd.

Conditions

Congenital Antithrombin DeficiencyDisseminated Intravascular Coagulation (DIC)

Phase 1

A Study of KW-3357 in Congenital Antithrombin Deficiency

CompletedNCT00938288

Kyowa Kirin Co., Ltd.Congenital Antithrombin Deficiency

Start: 2009-04-30End: 2011-04-30Updated: 2024-10-17

Phase 3

An Open-label Study of KW-3357

CompletedNCT01384903

Kyowa Kirin Co., Ltd.Disseminated Intravascular Coagulation (DIC)

Start: 2011-06-30End: 2013-05-31Updated: 2017-03-24

A Clinical Study of KW-3357 in Patients With DIC

CompletedNCT01384396

Kyowa Kirin Co., Ltd.Disseminated Intravascular Coagulation (DIC)

Start: 2011-12-31End: 2013-04-30Updated: 2017-03-24

A Phase 3 Clinical Study of KW-3357 in Patients With DIC

TerminatedNCT01384409

Kyowa Kirin Co., Ltd.Disseminated Intravascular Coagulation (DIC)

Start: 2012-02-29End: 2012-10-31Updated: 2017-03-24

Related Papers

An open-label, randomized, phase 3 study of the efficacy and safety of antithrombin gamma in patients with sepsis-induced disseminated intravascular coagulation syndrome.

2018-11-1621 citations